Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 following Single Ascending Dose Administration to Healthy Subjects who are Overweight or Obese

Study identifier:D8750C00001

ClinicalTrials.gov identifier:NCT05511025

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Phase I Randomized Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 following Single Ascending Dose Administration to Healthy Subjects who are Overweight or Obese

Medical condition

Healthy Participants

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD6234, Placebo

Sex

All

Estimated Enrollment

64

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 20 Sept 2022
Estimated Primary Completion Date: 19 Dec 2023
Estimated Study Completion Date: 19 Dec 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria